AssetMark Inc’s Syndax Pharmaceuticals SNDX Stock Holding History

AssetMark Inc’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$874	Hold	40	–	–	﹤0.01%	3177
2026 Q1	$934	Hold	40	–	–	﹤0.01%	3053
2025 Q4	$840	Hold	40	–	–	﹤0.01%	2984
2025 Q3	$615	Buy	+40	New	+$524	﹤0.01%	2896
2024 Q1	–	Sell	-10	Closed	-$216	–	2101
2023 Q4	$216	Buy	+10	New	+$154	﹤0.01%	1755

Other funds holding SNDX

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

VIG

Vienna Insurance Group Warsaw, Poland $381M AUM 105.39% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

AssetMark Inc's SNDX Position: Q2 2026 in Review

AssetMark Inc held its Syndax Pharmaceuticals (SNDX) position steady in Q2 2026 at 40 shares worth $874. The position accounts for ﹤0.01% of the portfolio, ranked #3177.

AssetMark Inc first reported a position in SNDX in Q4 2023 and has held it in 5 quarters since. The position peaked at $934 in Q1 2026. 56 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

AssetMark Inc held 40 shares of Syndax Pharmaceuticals worth $874 as of Q2 2026.
AssetMark Inc left its Syndax Pharmaceuticals share count unchanged in Q2 2026.
Syndax Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #3177 holding.
AssetMark Inc first reported a position in Syndax Pharmaceuticals in Q4 2023 and has held it in 5 quarters since.
AssetMark Inc's Syndax Pharmaceuticals position peaked at $934 in Q1 2026.
56 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.